Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of breast cancer patients in the study cohort

From: Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients

  Breast cancer (n = 266) IDC (n = 180)
Surgical treatment   
Lumpectomy 168 (63.1%) 113 (62.8%)
Mastectomy 84 (31.6%) 59 (32.8%)
Unknown 14 (5.3%) 8 (4.4%)
Age at diagnosis (years)   
Median (Range - 30.6–89.8) 59.2 59.2
< 59 126 (47.4%) 88 (48.9%)
≥ 59 140 (52.6) 92 (51.1%)
Adjuvant treatment   
Hormonal treatment   
Tamoxifen 131 (49.2%) 94 (52.2%)
Aromatase Inhibitor 13 (4.9%) 8 (4.4%)
Chemotherapy 73 (2.7%) 66 (24.8%)
Radiotherapy 149 (56.0%) 101 (56.1%)
Therapy details not available 6 (2.2%) 6 (3.3%)
Tumor size (cm)   
Mean ± SD 1.85 ± 1.525 1.82 ± 1.466
Minimum 0.1 0.1
Maximum 9 9
≤2 cm 198 81
>2 cm 57 96
Unknown 11 3
AJCC pTNM stage (n, %)   
0 (DCIS + LCIS) 62 (23.3%) -
I 94 (35.3%) 113(62.8%)
II 87 (32.7%) 58 (32.2%)
III 6 (2.3%) 5 (2.8%)
IV 17 (6.4%) 4 (2.2%)
Estrogen receptor (ER)   
Negative 35 (13.1%) 33 (18.3%)
Positive 161 (60.6%) 136 (75.6%)
Unknown 70 (26.3%) 11 (6.1%)
Progesterone receptor (PR)   
Negative 71(26.7%) 64 (35.6%)
Positive 123 (46.2%) 103 (57.2%)
Unknown 72 (27.1%) 13 (7.2%)
Grade   
I 56 (21.1%) 42 (23.3%)
II 106 (39.8%) 66 (36.7%)
III 85 (32.0%) 65 (36.1%)
Unknown 19 (7.1%) 7 (3.9%)
Nodal status   
Negative 204 (76.7%) 123 (68.3%)
Positive 62 (23.3%) 57 (31.7%)